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1. Introduction   
Neoplasms, which arise in cells originating from central nervous system (CNS) or peripheral 
nervous system (PNS) result in a class of tumours called neuroectodermal tumours. 
Generally after development ceases, neurons become post-mitotic and only the glial cells 
retain the capacity to divide and proliferate. So it is quite appreciable that most of the brain 
tumours are of glial origin and are referred as gliomas. Based on the cell type involved in 
malignancy, gliomas can be astrocytomas (astrocytes), oligodendrogliomas 
(oligodendrocytes), oligoastrocytomas (mixture of astrocytes and oligodendrocytes) and 
ependymomas (ependymal cells). Astrocytomas account for more than 60% of all primary 
brain tumours hence forming the majority of neoplasms of the CNS. On the other hand, 
neurofibroma and schwannoma are the two most common glial tumours of the PNS.  
According to WHO (2007) classification, astrocytomas are classified into grades I–IV based 
on the intensity of malignancy as determined by histopathological criteria. Grade I (Pilocytic 
astrocytoma; PA) gliomas are generally benign and often circumscribed, whereas grade II 
(Diffuse astrocytoma; DA), III (Anaplastic astrocytoma; AA) and IV (Glioblastoma; GBM) 
gliomas are malignant and they diffusely infiltrate the brain. The most malignant and 
common form of infiltrating astrocytic tumours is glioblastoma with a median survival of 
less than one year.  GBM can be further divided into two subtypes based on certain genetic 
and clinical features: primary and secondary GBM. Primary GBM arises as a de novo process, 
without any antecedent history of low grade lesions, whereas secondary GBM develops 
progressively from lower grades, generally over a period of 5–10 years.  
Like any other neoplasm, the underlying cause of gliomagenesis is the genomic alterations 
like deletions, amplifications, mutations, aberrant DNA methylation and chromosomal 
rearrangements, which result in the activation of oncogenes and inactivation of tumour 
suppressors. With the discovery of hundreds of miRNA genes in the past few years that 
produce non-coding RNA transcripts with no significant open reading frame, it has become 
evident that the genomic complexity of the cancer cell is far greater than expected.  
miRNAs are single-stranded non coding RNAs of 19–25 nucleotides in length, generated 
from endogenous transcripts that contain a local hairpin structure. They function as guide 
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molecules in post-transcriptional gene silencing by base pairing with target mRNAs, leading 
either to the cleavage of the target mRNA or its translational repression. miRNAs are one of 
the largest gene families, accounting for ~1% of the genome (Kim, 2005). According to recent 
studies, miRNAs play key roles in diverse regulatory pathways which control development, 
differentiation, apoptosis, cell proliferation and organogenesis. miRNAs and their targets 
seem to form intricate regulatory networks, as a single miRNA can bind to and regulate 
different mRNA targets and conversely, a single mRNA can be synergistically controlled by 
multiple miRNAs. Recently, the work by the Bartel and Burge laboratories predicted that 
over one third of the human genes are regulated by miRNAs (Lewis et al., 2005).  
The location of miRNA genes in fragile sites of the genome provides a circumstantial 
evidence of an etiological role of miRNAs in tumour formation. Because miRNAs are 
generally negative regulators of gene expression, changes in the amounts of these RNAs can 
be tumorigenic if they target a tumour suppressor or an oncogene. For example, over 
accumulation of an miRNA that targets a tumour suppressor would result in less of that 
protective factor. In contrast, reduced accumulation of an miRNA that targets a proto-
oncogene could lead to excessive amounts of the oncogenic protein. Either way, the net 
outcome is an imbalance in the activities of tumour suppressor genes and oncogenes, hence 
resulting in malignancy.   
We review here the discovery and biology of miRNAs including their structure, regulation 
and biogenesis along with different methods available today to assay miRNA expression. A 
detailed account of the literature on differential miRNA expression and their functional 
characterization in glioma is provided. In addition, the potential utility of miRNAs in 
glioma diagnosis, classification, prognosis and targeted therapy is also discussed.  
2. Discovery and biology of miRNAs   
miRNAs were initially discovered as small temporal RNAs (stRNAs) that played a role in 
the developmental transitions in Caenorhabditis elegans. The first miRNA to be discovered 
was lin-4 in C. elegans in the year 1993 (Lee et al., 1993). The discovery of lin-4 and its target 
specific translational repression pointed to a new way of gene regulation. In the year 2000, 
the second miRNA, let-7 was discovered in the same organism and since then a huge 
number of miRNAs have been discovered. A total of 15172 miRNA entries have been 
recorded so far from various organisms (Release 16, miRBase) which also include 1048 
miRNAs from Homo sapiens (http://www.mirbase.org/).  
A small RNA must fulfill the following criteria to be classified as an miRNA. Its expression 
should be authenticated by hybridization to a size-fractionated RNA sample by employing 
northern blotting. It should be detected by methods like PCR after reverse transcription of 
RNA (RT-PCR), primer extension analysis, RNase protection assay and microarray. 
However, northern blotting remains the method of choice for the confirmation of miRNAs, 
as the blot generally detects both the mature form (a ~22-nucleotide band) and the hairpin 
precursor (a ~70-nucleotide band) of the predicted miRNA. The small RNA sequence must 
exist in the stem portion of the hairpin precursor. The precursors are ~60–80 nucleotides in 
animals, but the lengths are more variable in plants. In addition, the small RNA sequences 
should be conserved phylogenetically. Lastly, the evidence can be consolidated if the 
precursor of the predicted miRNA accumulates in ablated Dicer background. However, this 
criterion is not in vogue, because of the technical challenges that are involved in depleting 
Dicer in different cells. 
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2.1 miRNA gene structure 
Most of the miRNA genes are transcribed as independent transcription units. The 
transcripts thus synthesized are referred as primary miRNAs and are equipped with a 7-
methyl guanosine cap in the 5' end as well as a poly A tail in the 3' end which are the unique 
features of class II gene transcripts. This evidence supports the fact that majority of miRNAs, 
if not all, are transcribed by RNA polymerase II (Lee et al., 2004). Treatment of human cells 
with ǂ-amanitin at levels which inhibit RNA polymerase II activity, also brings down the 
global levels of primary miRNAs. Furthermore, chromatin immunoprecipitation (ChIP) 
experiments have also revealed the physical association of RNA polymerase II with miRNA 
promoters and thereby establishing the fact that miRNAs are RNA polymerase II 
transcribed. 
miRNAs can be transcribed either individually i.e. a single primary transcript gives rise to a 
single mature miRNA or they can be transcribed in a polycistronic fashion, in which case 
distinct miRNAs are produced from a single primary transcript. The miRNAs arising from a 
single gene cluster can be related to each other, suggesting that the miRNAs might have 
assembled as a result of gene duplication and may be playing a synergistic role in the 
production of a particular phenotype. 
Based on the genomic location of the transcription units of miRNAs, they can be grouped 
broadly as: intergenic miRNAs and intragenic miRNAs. Intergenic miRNAs exist as 
independent genetic elements, their transcription being driven by their own promoter. The 
intragenic class can be either intronic or exonic in nature owing to the fact whether the stem 
loop sequence of the precursor miRNA comes from the intron or exon of the protein coding 
gene or sometimes a non-protein coding gene. In both types, the miRNA gene can be mono 
or polycistronic. The expression of intragenic miRNAs can be either controlled by their own 
independent promoter or the miRNAs would be co-transcribed with the parent gene, in 
which case the pre-miRNA would be processed subsequent to intron splicing. Some 
miRNAs derive their stem loop sequence from rather short introns and hence bypass the 
processing action of Drosha and are called Mirtrons (Ruby et al., 2007).  
2.2 miRNA gene regulation 
The expression of miRNAs can be modulated at a number of levels, which broadly include 
the transcription of the primary transcript and the multiple steps of the miRNA biogenesis. 
But it continues to remain a dilemma that which step is regulated and how the regulation is 
achieved. Regulation at the level of transcription seems more likely to be the major control 
mechanism. A number of RNA polymearse II associated transcription factors regulate the 
expression of miRNA genes, for instance TP53, a tumour suppressor, transactivates the miR-
34 family of miRNAs (He et al., 2007). Overall, the expression of a particular miRNA seems 
to be under the control of developmental and tissue specific signalling. Apart from this, 
there are reports that miRNAs are also modulated post transcriptionally. Post 
transcriptional regulation is attributed to differential Drosha processing. An example of post 
transcriptional regulation involves the induction of miR-21 in response to bone 
morphogenetic protein (BMP) / transforming growth factor beta (TGF-ǃ) signalling without 
actual transcriptional activation (Davis et al., 2008). TGF-ǃ and BMP signalling activates the 
Smad mediated Drosha processing of the pri-miR-21. 
Majority of miRNA genes being transcribed by the same RNA polymerase as protein coding 
genes, the mechanisms of epigenetic control known for protein coding genes are likely to be 
applicable to miRNA loci as well. Aberrant DNA methylation of tumour suppressor genes is 
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a common occurrence in cancer; accordingly several miRNA loci including miR-9-1, miR-
193a, miR-137, miR-342, miR-203 and miR-34b/c, are found to be hypermethylated in 
multiple human cancers (Lujambio et al., 2008). Conversely, the let-7a-3 locus is 
hypomethylated in lung adenocarcinoma and elevated expression of this locus results in 
enhanced oncogenic gene transcription (Brueckner et al., 2007;). miRNA promoters are also 
regulated by histone modifications during development and pathogenesis (Davis and Hata, 
2009).  
2.3 Biogenesis of miRNAs 
miRNA biogenesis involves initial transcription as a largely unstructured precursor, termed 
as primary miRNA (pri-miRNA), which is subsequently processed in the nucleus to give 
rise to a 70-nucleotide precursor miRNA hairpin intermediate (pre-miRNA). The pre-
miRNA gets transported to the cytoplasm where it undergoes further processing to give rise 
to a mature miRNA (Figure.1). 
Most of the miRNA genes are transcribed by RNA polymerase II to generate a stem-loop 
containing primary miRNA (pri-miRNA), which can range in size from hundreds of 
nucleotides to tens of kilobases (Lee et al., 2004). Like mRNAs, RNA polymerase II 
transcribed pri-miRNAs contain 5' cap structures, are polyadenylated, and may be spliced 
(Cai et al., 2004). The pri-miRNA is processed within the nucleus by a multiprotein complex 
called the microprocessor. The microprocessor is a 650 kDa complex in humans and is 
constituted by two key components: Drosha, an RNase III enzyme and DiGeorge syndrome 
critical region 8 gene (DGCR8), a double-stranded RNA-binding domain (dsRBD) protein 
(Gregory et al., 2004; Landthaler et al., 2004). DGCR8 is also known as Pasha in D. 
melanogaster and C. elegans. The activity of Drosha and DGCR8 results in the production of a ∼70 nucleotide hairpin structure known as the precursor miRNA (pre-miRNA). The 2-
nucleotide 3' overhang, characteristic of RNase III mediated cleavage, is recognized by 
exportin-5, which transports the pre-miRNA into the cytoplasm via a Ran-GTP-dependent 
mechanism (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2003). The pre-miRNA is finally 
cleaved off the loop to produce the mature miRNA duplex about 22 nucleotide in length by 
Dicer, yet another member of RNase III superfamily of bidentate nucleases.  
Dicer is accompanied by dsRBD proteins like TRBP (TAR-RNA binding protein) 
(Chendrimada et al., 2005; Lee et al., 2006). Dicer and TRBP recruit members of the 
Argonaute family and the trimeric complex thus formed is referred to as RNA Induced 
Silencing Complex (RISC) (Gregory et al., 2005; Maniataki and Mourelatos, 2005). Argonaute 
proteins form the catalytic component of the RISC complex as they aid in strand selection of 
the miRNA duplex in addition to the possession of slicer activity by virtue of which they 
slice the target mRNA. In mammals, Ago2 is the sole enzyme equipped with 
endonucleolytic activity (Liu et al., 2004; Meister et al., 2004). One of the miRNA strands 
which has relatively less stability at the 5' end is incorporated into the RISC complex while 
as the other miRNA strand is generally degraded (Du and Zamore, 2005). It is often possible 
that both strands of the miRNA duplex could function as mature miRNAs but their 
abundance may be drastically different (Ruby et al., 2006).   
The miRNA then guides the RISC to specific mRNA targets, the basis of which is sequence 
complementarity generally in the 3' UTR of the target mRNA. In cases of perfect or near 
perfect complementarity to the mRNA, the target mRNA can be cleaved and degraded and 
if there is less complementarity, it results in translational repression (Hutvagner and 
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Zamore, 2002). Most animal miRNAs bind imperfectly to their targets and promote 
translational repression, rather than cleavage and degradation. However, the seed sequence 
representing 2-8 nucleotides from the 5’ end of miRNA requires a perfect complementarity. 
The mechanism of translational repression is somewhat vague with some evidences 
suggesting that miRNAs block translational initiation while as others suggest a block in 
elongation.   
 
 
 
Fig. 1. Schematic representation of miRNA biogenesis pathway. 
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3. Methods to quantitate miRNA levels 
An array of techniques and methodologies can be employed to quantify the levels of 
miRNAs both absolutely and relatively. These include northern blotting, microarrays, bead 
based arrays and quantitative real-time RT-PCR. Northern blotting is a low throughput 
technique as well as less sensitive requiring more input RNA but it can be used to detect 
both mature and pre-miRNA molecules. Genome wide miRNA expression studies are 
chiefly carried out by employing various microarray platforms provided by different private 
firms and are based on different concepts. 
Microarray based detection involves a set of oligonucleotide probes which are spotted on a 
glass slide and can capture the small molecule RNAs like miRNAs, if allowed to hybridize 
under optimum conditions. Availability of high density microarrays, where one can spot 
several thousands of oligonucleotide probes, provides the liberty to detect hundreds of 
miRNAs simultaneously on a single slide. Agilent Inc (http://www.agilent.com/) has 
developed a microarray based application for studying miRNAs that combines a unique 
miRNA direct labeling method with an innovative probe design and established high-
performance SurePrint inkjet synthesis technology. miRNAs being small in size have an 
inherent limitation to hybridize at a single melting temperature (Tm) without compromising 
the sensitivity and specificity of the method. This problem has been overcome by employing 
locked nucleic acids (LNAs) developed by Exiqon Inc (http://www.exiqon.com/). Locked 
nucleic acids differ from regular nucleic acids by a methylene bridge between 2’ oxygen 
atom and the 4’ carbon atom of the ribose moiety. LNA monomers increase the Tm of the 
nucleic acid duplex by 2-10˚C and hence by adjusting the number of LNA units in the 
oligonucleotide, the hybridization can be carried out at a higher temperature thereby 
increasing the specificity.  
Bead-based arrays also allow simultaneous quantification of hundreds of miRNAs (Luminex 
Inc). This methodology also uses oligonucleotide probes which are coupled to carboxylated 
polystyrene microspheres that incorporate variable mixtures of two fluorescent dyes hence 
allows the detection of each microsphere with a distinct color by a flow cytometer. Each 
microsphere is coupled with oligonucleotide molecules that are specific for a particular 
miRNA. The method involves RNA extraction, followed by biotinylation and finally 
hybridization. The microspheres are washed, incubated with streptavidin–phycoerythrin, 
and analyzed on a Luminex analyzer. The analyzer identifies the fluorescent microsphere as 
well as quantitates the intensity of the streptavidin–phycoerythrin fluorescence, resulting in 
the identification of miRNAs present in the sample.  
Expression analysis is more commonly performed by quantitative real-time RT-PCR. 
Quantification of mature miRNAs usually involves reverse transcription of the miRNA with 
a stem–loop primer. miRNA specific cDNA is then used in the real-time PCR reaction. A 
mixture of forward and reverse primers and a dual-labeled probe (TaqMan®) are used to 
amplify and detect the specific cDNA (Life Technologies Corp.). The probe has a reporter 
dye on the 5’ end and a quencher on the 3’ end. If the target sequence is present during the 
PCR, the probe binds to the target sequence. During the extension stage of the PCR cycle, 
the reporter dye is released by the 5’ exonuclease activity of Taq polymerase, and because 
the reporter and quencher have been separated, the fluorescence from the reporter dye is 
detected. A variation of quantitative real time RT-PCR using SybrGreen based chemistry has 
also been employed (System Biosciences, Qiagen etc.). The technique involves cDNA 
synthesis for the miRNA pool followed by real time PCR using a miRNA specific forward 
primer and a reverse primer essentially derived from RT primer.  
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4. miRNA regulation in glioma 
Since the initial reports by Ciafre et al and Chan et al, there is an increasing body of literature 
accumulated on the role of miRNAs in glioma development (Table. 1) (Chan et al., 2005; 
Ciafre et al., 2005). Various miRNA profiling studies carried out in glioma tissue samples 
identified differentially regulated miRNAs in gliomas. Several studies also reported the in-
depth investigation of specific miRNAs in glioma cells including functional characterization 
to understand the effects of regulation of miRNA in glioma cells with respect to various 
transformation related phenotypes like cell proliferation, cell death, migration and invasion. 
Many of these studies also included the prediction and experimental validation of targets of 
miRNA by using various accepted techniques.   
4.1 Large scale expression profiling of miRNAs in glioma 
The first report of expression profiling of large number of miRNAs in glioma was almost 
simultaneously reported by two groups (Chan et al., 2005; Ciafre et al., 2005). Ciafre et al 
used a microarray chip to profile the expression of 245 miRNAs in GBM tissue samples 
(Ciafre et al., 2005). The samples included nine GBM tissue samples, matched adjacent 
peripheral region as normal brain tissue and glioma cell lines. With the additional 
validation by northern blotting, this study identified miR-221 as GBM upregulated and 
miR-128, miR-181a, miR-181b and miR-181c as GBM downregulated miRNAs. Chan et al 
analyzed the expression of 180 mammalian miRNAs using a nylon membrane based 
oligonucleotide array in three primary high-grade gliomas and eight non-neoplastic fetal 
and adult brain tissues. They found miR-21 as the most upregulated miRNA in high grade 
gliomas among a total eight miRNAs (Chan et al., 2005). Silber et al analyzed the 
expression of 192 miRNAs by quantitative RT-qPCR with four AAs, four GBMs and four 
Glioses (as normal brain tissues) and found that 35 miRNAs were significantly 
deregulated in AA or GBM tumours (Silber et al., 2008). Thirteen (37%) of these miRNAs 
were differentially expressed in both AA and GBM in comparison to glioses, 16 (45%) 
were differentially expressed only in GBM tumours and 6 (17%) were differentially 
expressed only in AA tumours. Another study carried out microarray based expression 
profiling of 245 miRNAs and found that eleven miRNAs were downregulated and eight 
miRNAs were upregulated in GBM (Godlewski et al., 2008). Malzkorn et al analyzed the 
expression of 157 miRNAs in four glioma patients who had the progression of grade II to 
grade IV by real time RT-PCR (Malzkorn et al.). This revealed the differential expression 
of 14 miRNAs – of which, 12 miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-
20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) were upregulated during 
progression whereas 2 (miR-184 and miR-328) of them were downregulated (Malzkorn et 
al.). The authors validated the expression of selected miRNAs (miR-16, miR-17, miR-19a, 
miR-20a, miR-140 and miR-184) in an independent set of low grade and secondary GBM 
samples thus confirming the grade associated regulation of these miRNAs. Modulation of 
miR-17 and miR-328 in glioma cell lines revealed an important role of these miRNAs in 
glioma cell proliferation, apoptosis and cell invasion phenotypes (Malzkorn et al.).  
While the above studies were relatively small, investigating couple of hundred miRNAs and 
used fewer tissue samples, Rao et al recently profiled the expression of 756 human miRNAs 
in malignant astrocytoma- AA (n=13) and GBM (n=26), along with the normal brain 
samples (n=7) and found that 55 miRNAs were upregulated and 29 miRNAs were 
downregulated in malignant astrocytomas in comparison to normal brain samples  
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* miRNAs are classified to have ‘oncogenic’ or ‘tumour suppressor’ function based on their pro-tumo
property respectively.   
** miRNA targets are identified based on the reduction in the protein level with miRNA overexpress
in the reporter activity of the 3’-UTR reporter.   
*** miRNA site confirmation indicates whether the predicted miRNA binding site is confirmed by si
abolishes the effects of miRNA overexpression on the reporter activity.   
Table 1. Characterization of the role of miRNAs in glioma 
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(Rao et al.). Besides the validation of several deregulated miRNAs, this study also developed 
a 23 miRNA expression signature that could distinguish between AA and GBM with high 
accuracy. 
4.2 Specific miRNAs in glioma development  
4.2.1 miR-21 
miR-21 is found to be upregulated in different kinds of human cancers including glioma. 
miR-21, being one of the well studied miRNAs in cancer, is shown to have oncogenic roles 
by targeting multiple tumour suppressors in human cancers. The expression profiling of 
miRNAs in glioblastoma tissues as well as in glioma cell lines identified miR-21 as an 
upregulated miRNA in glioma (Chan et al., 2005). Subsequently, the over expression of miR-
21 in gliomas was confirmed by several studies (Ciafre et al., 2005; Conti et al., 2009; Gabriely 
et al., 2008); (Papagiannakopoulos et al., 2008; Rao et al., ; Silber et al., 2008).   
Modulation of miRNA levels in glioma cell lines indicated that miR-21 had pro-proliferative 
(Chan et al., 2005; Papagiannakopoulos et al., 2008; Zhou et al.) and anti-apoptotic effects 
(Chan et al., 2005; Papagiannakopoulos et al., 2008). miR-21 also affected cell cycle 
progression (Papagiannakopoulos et al., 2008) and the tumour growth in vivo (Corsten et al., 
2007; Zhou et al.). miR-21 was also shown to modulate the chemosensitivity of glioma cells 
to many chemotherapeutic agents like doxorubicin, secretable tumour necrosis factor related 
apoptosis inducing ligand (S-TRAIL), taxol, VM-26 and temozolomide (Corsten et al., 2007; 
Li et al., 2009b; Papagiannakopoulos et al., 2008; Ren et al., ; Shi et al.). Papagiannakopoulos et 
al undertook systems biology approach to understand the role of miR-21 in glioblastoma 
development. The network analysis of bioinformatically predicted targets of miR-21 showed 
that the over expressed miRNA was linked to three major cancer pathways – p53, TGF beta 
and mitochondrial apoptosis pathways. The knock down of miR-21 in glioma cell line 
upregulated many tumour suppressor proteins like p53, Bax, DAXX, APAF1, p21, TAp63 
and TGFBR2 (Papagiannakopoulos et al., 2008).   
Since miR-21 is one of the most upregulated miRNAs, efforts are being made to identify its 
direct targets. While the tumour suppressor proteins like PTEN (phosphatase and tensin 
homolog), TPM1 (Tropomyosin 1) and maspin were well characterized as direct targets of 
miR-21 in other cancers, they were not validated in glioblastoma (Novakova et al., 2009). 
Nevertheless, it was shown that the anti-apoptotic nature of the miR-21 can be partly 
attributed to its target PDCD4 (programmed cell death 4), as the over-expression of miR-21 
inhibited PDCD4-dependent apoptosis (Chen et al., 2008). In addition to its effects on 
growth, miR-21 also affected the property of invasion that causes infiltrating pattern of 
glioma growth in vivo (Gabriely et al., 2008). Using the target prediction algorithms and the 
transcript profiling, the matrix metalloprotease inhibitors, RECK and TIMP3 were identified 
as miR-21 targets thus substantiating a pro-invasion and -migration role for miR-21 
(Gabriely et al., 2008). The promotion of invasion was also attributed to another target of 
miR-21, sprouty, the negative regulator of Ras/MAPK pathways (Kwak et al.).  
4.2.2 miR-26a 
The upregulation of miR-26a and its consequence on cellular pathways leading to the pro-
tumorigenic effects are well studied in glioblastoma. In GBM, PTEN expression was found 
to be directly regulated by miR-26a (Huse et al., 2009). The miR-26a locus was found to be 
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amplified and it was often associated with the monoallelic loss of PTEN suggesting that the 
residual PTEN transcript made in PTEN +/- cases was nullified by miR-26a, analogous to 
loss of heterozygosity. Using The Cancer Genome Atlas (TCGA) data, authors demonstrated 
that, in patients with monoallelic PTEN deletion, amplification of miR-26a locus served as 
another mechanism to inactivate PTEN. In the mouse glioma model, miR-26a mediated 
PTEN repression enhanced tumour formation and substituted the loss of heterozygosity of 
PTEN locus. Further studies carried out by Kim et al demonstrated that hsa-miR-26a is a 
cooperating component of a frequently occurring oncogenic amplicon containing CDK4 and 
CENTG1 which regulate the RB1 and PI3 kinase/AKT pathways (Kim et al.). By integrating 
the TCGA data for copy number, mRNA, miRNA, and DNA methylation, they identified 
PTEN, RB1, and MAP3K2/MEKK2 to be the functional targets of miR-26a in GBM. They 
also demonstrated that miR-26a alone could transform NIH3T3 cells and promote the 
growth of glioma cells in vivo by directly regulating the expressions of PTEN, RB1, and 
MAP3K2/MEKK2. This led to the increased AKT activation and decreased c-JUN N-
terminal kinase-dependent apoptosis resulting in increased proliferation. In both PTEN-
positive and PTEN-deficient glioma cells, the over expression of miR-26a induced the 
tumour growth in vivo, and it was further increased if the cells were over expressing CDK4 
or CENTG1. GBM patients with the amplification of miR-26a-CDK4 locus had markedly 
decreased survival. Thus, the amplification of hsa-miR-26a, CDK4, and CENTG1 increased 
the aggressiveness of the tumour by cooperately regulating RB1, PI3K/AKT, and JNK 
pathways (Kim et al.).  
4.2.3 miR-221 and miR-222  
The comprehensive analysis of miRNA expression during serum stimulation of quiescent 
T98 glioblastoma cells revealed that miR-221 and miR-222 were upregulated as cells 
progressed beyond the G1-S phase transition (Medina et al., 2008). miR-221 and miR-222 
were found to target CDK inhibitors- p27 and p57 and prevent quiescence when elevated 
during growth factor deprivation and induced cell death by causing precocious S-phase 
entry. Further, the inhibition of the expression of these miRNAs in glioma cell lines led to 
the increased apoptosis (Zhang et al.). The effect of the miRNA on apoptosis was also 
attributed to its ability to target pro-apoptotic gene PUMA. The over expression of PUMA 
reversed the phenotypes caused by the over expression of the miRNAs. In tumour xenograft 
model, inhibition of miR-221/222 reduced the tumour volume compared to the scramble 
control along with increased apoptosis, reduced Ki-67 staining, increased PUMA and Bax 
and reduced Bcl-2 expression. In human glioma tissue samples, the down regulation of 
PUMA negatively correlated with the upregulation of miR-221/222 suggesting the 
importance of the regulation in the clinical samples.  
4.2.4 miR-296 
The profiling of miRNAs upon co-culturing human brain endothelial cells (HBMVECs) 
with human glioma cell line U87 identified that miR-296 is the only upregulated miRNA 
(Wurdinger et al., 2008). The miR-296 expression also increased in HBMVECs upon 
treatment with angiogenic factors like EGM, VEGF and EGF. Treatment of HBMVECs 
with VEGF resulted in the tubule formation, increased the migration distance and also 
increased the miR-296 level in dose dependent manner. Treatment of cells with miR-296 
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inhibitors led to decreased tubule formation and migration distance. On the other hand, 
the overexpression of the miRNA led to increased tubule formation. The target prediction 
algorithms and subsequently, experimental evidences suggested that HGS, hepatocyte 
growth factor regulated receptor kinase substrate, to be the target of the miR-296. HGS 
was previously known to regulate the levels of VEGFR2 and PDGFRǃ receptors. These 
studies suggested that the miR-296 in HBMVECs target HGS with the resultant 
upregulation of VEGFR2 and PDGFRǃ receptors thereby promoting angiogenesis. To 
understand the in vivo role of miR-296 in tumour angiogenesis, nude mice-bearing 
subcutaneous U87 xenografts were injected with cholesterol-conjugated miR-296 antisense 
oligonucleotide. The quantification of tumour neovascularization revealed that the mice 
injected with antisense miR-296 showed reduced tumour neovascularization as compared 
to the mice injected with the mismatch control. The endothelial cells derived from human 
glioma showed upregulation of miR-296 compared to the normal brain with concomitant 
downregulation of HGS and the upregulation of the receptors-VEGFR2 and PDGFRǃ. 
These observations demonstrate the importance of miR-296 in the angiogenesis of 
malignant glioma. 
4.2.5 miR-7 
miR-7 was found to be a tumour suppressor miRNA and was downregulated in glioma 
compared to the normal brain. The in vivo experiments suggested that re-expression of miR-
7 into glioma cells decreased the cell count, invasion and increased apoptosis (Kefas et al., 
2008). Oncogenic proteins, EGFR, IRS-1 and IRS-2 were identified as the targets of miR-7. 
The miR-7 inhibited the Akt pathway but this inhibition could not be rescued by the over 
expression of wild type or the mutant EGFR. Further investigation revealed that the 
impaired processing as the mechanism of downregulation of miR-7 in glioma. 
This study unraveled the tumour suppressor property of the miR-7 by targeting the 
receptors-EGFR, IRS1 and IRS2, thereby counteracting the pro-proliferative effect of the 
pathway.  
4.2.6 miR-34a 
miR-34a was found to act as a tumour suppressor in glioma by targeting multiple oncogenes 
like c-Met, Notch1, Notch2 and CDK6 (Li et al., 2009a). The miR-34a expression in glioma 
tissues was downregulated compared to the normal brain. As the earlier reports suggested 
that miR-34a is a target of p53, authors analyzed the expression of the miRNA in cell lines 
with wild type p53 and with mutant p53 and found that the expression of miR-34a in 
mutant p53 is lower compared to that in those cell lines bearing wild type p53. In the glioma 
tissues, the c-Met and the miR-34a expression negatively correlated suggesting the miRNA 
mediated regulation of c-Met in glioma. To assess the effect of the miRNA on cell 
proliferation, cell cycle and apoptosis, the miR-34a was over expressed in different cell lines, 
along with human astrocytes. The miR-34a over expression reduced the proliferation, the 
increased G1/G0 population only in cancer cell lines, but not in normal human astrocytes. 
The invasion of the cells also decreased with miR-34a over expression. The over expression 
of c-met partially but significantly rescued the effect of miR-34a over expression on cell cycle 
where as the over expression of Notch1 and Notch2 rescued miR-34a effect on apoptosis. In 
vivo studies suggested that the miR-34a over expression in U87 cells led to the development 
of much smaller tumours compared to the control U87 cells. 
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4.2.7 miR-124 and miR-137 
Expression profiling revealed that the levels of miR-124 and miR-137 were significantly 
decreased in AA and GBM relative to non-neoplastic brain tissue (Silber et al., 2008). During 
the differentiation of cultured mouse neural stem cells following growth factor withdrawal, 
the levels of these miRNAs were increased. The re-expression of these miRNAs with the 
DNA methylation inhibitor treatment suggested a possible regulation of these miRNAs by 
epigenetic phenomenon like methylation. The over expression of miR-124 or miR-137 
induced morphological changes and also induced differentiation marker profile. Further 
studies identified that miR-124 and miR-137 target CDK6 resulting in reduced 
phosphorylated RB and G1 cell cycle arrest. 
4.2.8 miR-128  
The expression analysis revealed that miR-128 was downregulated miRNAs in glioma 
(Godlewski et al., 2008; Zhang et al., 2009). Over expression of the miRNA led to the 
decreased cell proliferation and tumour growth in vivo (Godlewski et al., 2008) suggesting 
the tumour suppressor nature of the miRNA. miR-128 was shown to target Bmi1 (B 
lymphoma mouse Moloney leukemia virus insertion region) oncogene. In the GBM 
tumours, the downregulation of miR-128 correlated with the corresponding upregulation of 
Bmi1 oncogene. The miR-128 over expression caused the reduction of H3K trimethylation 
and pAkt and also increased p21 suggesting that the cellular pathways regulated by Bmi1 
were altered with miRNA over expression leading to the decreased neurosphere formation. 
miR-128 was also shown to directly target E2F3a transcription factor generally upregulated 
in glioma. The over expression of E2F3a rescued the cell growth inhibition caused by the 
over expression of the miR-128 (Zhang et al., 2009).  
4.2.9 miR-218 
miR-218 had reduced expression in glioma cell lines compared to the normal brain (Song et 
al.). The over expression of the miRNA in glioma cell lines resulted in the decreased 
migration and invasion of the glioma cells with concomitant decreased MMP-9 activity. The 
over expression of miR-218 in glioma cell lines also resulted in the downregulation of the 
targets of NF-kB pathway suggesting the role of the miRNA in regulating the pathway. 
Using the target prediction algorithms, authors identified that miR-218 targeted IKK-ǃ 
thereby regulating NF-κB pathway (Song et al.). 
4.2.10 miR-125b 
The expression of miR-125, a previously identified brain-specific miRNA, was found to be 
reduced when glioma cells were treated with all trans retinoic acid (ATRA) (Xia et al., 2009c). 
The over expression of miR-125b increased the cell viability in the presence or in the absence 
of ATRA along with the decrease in the apoptosis. The authors identified Bmf (Bcl-2 
modifying factor) as the direct target of miR-125b. In contrast to this report, another study 
reported that the over expression of miR-125b in glioma cells led to the decreased cell 
growth and caused the reduced progression of the cells through cell cycle by 
downregulating the levels of CDK6 and CDC25 (Shi et al.). The study also reported that 
miR-125b was expressed at a higher level in CD133 positive glioma stem cells compared to 
the CD133 negative non-stem cell population.   
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4.2.11 miR-451 
miR-451 is one of the significantly downregulated miRNA in glioma compared to the 
normal brain (Nan et al.). The over expression of miR-451 in glioma cell lines led to 
decreased proliferation and invasion, in addition to Go/G1 arrest and apoptosis induction. 
The over expression of miR-451 reduced Akt, cyclinD1, MMP2, MMP9 and Bcl-2 also 
increased p27/kip levels suggesting the tumour suppressor nature of the miRNA. However, 
the above identified miR-451 targets have not been experimentally validated (Nan et al.).  
4.2.12 miR-15b 
The modulation of miR-15b in U87 and U118 glioma cell lines demonstrated that miR-15b 
affects the cell growth and the cell cycle progression (Xia et al., 2009a). The bioinformatics 
prediction identified cyclins- cyclin E1 and cyclin D to be the targets of miR-15b. The 
authors further demonstrated that cyclin E1 was indeed a direct target of miR-15b.   
4.2.13 miR-181a and miR-181b 
The miRNAs- miR-181a and miR-181b were found to be downregulated in glioma by 
multiple studies (Ciafre et al., 2005; Conti et al., 2009; Malzkorn et al.). The overexpression of 
these miRNAs in glioma cell lines resulted in the reduction of cell growth in vivo, anchorage 
independent growth, invasion and apoptosis (Shi et al., 2008).  
4.2.14 miR-146b  
The modulation of miR-146b in glioma cell line revealed that the migration and invasion 
were inhibited by miR-146b (Katakowski et al., ; Xia et al., 2009b). miR-146 was found to 
target MMP-16 which could potentially mediate the reduced migration and invasion seen 
upon miR-146b overexpression (Xia et al., 2009b). miR-146b was also shown to directly 
target EGFR (Katakowski et al).  
5. Applications of miRNA in glioma: accurate grading, better prognosis and 
novel therapeutic approaches 
The rationale for using miRNAs in glioma diagnosis and therapeutic modalities is as 
follows. The identification of differences in the genetic alterations in miRNA genes and 
miRNA transcript levels in tumour samples compared to normal tissues provides an 
automatic basis for their utility for glioma diagnosis, classification and prognosis. In fact, 
classification of multiple cancers based on the expression pattern of couple of hundred 
miRNAs was found to be more accurate than using expression of approximately 16,000 
protein coding genes (Lu et al., 2005). Even though several miRNAs have been shown to be 
regulated in different grades of glioma, variation in the expression of individual miRNAs 
within a glioma grade suggests that distinct subgroups within each grade of glioma could 
be identified. It is likely that these subgroups may have different prognosis. miRNAs also 
appear to be an attractive target for therapeutic intervention because the aberrantly 
expressed miRNAs seem to play key role in the development of cancer and that correcting 
the miRNA deficiencies either by antagonizing or restoring miRNA function may offer a 
therapeutic gain (Bader et al.).   
Although several miRNAs have been identified to be either upregulated or down regulated 
in glioblastoma, there were only few studies which particularly investigated the differential 
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regulation of miRNAs between different grades of glioma. Real time RT-PCR analysis of 
several miRNAs in WHO grade II and grade IV samples which spontaneously progressed 
from the same set of patients identified twelve miRNAs (miR-9, miR-15a, miR-16, miR-17, 
miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) to be 
upregulated and two miRNAs (miR-184 and miR-328) to be downregulated in grade IV 
tumours thus characterizing their role in progression (Malzkorn et al.). Analysis of miRNA 
microarray data by prediction analysis of microarrays (PAM), a 23 miRNA expression 
signature was identified that could distinguish GBM (grade IV) from AA (grade III) with an 
accuracy of  95% (Rao et al.). 
While many studies identifying an individual miRNA or miRNA expression signatures 
predicting patient survival in several cancers like lung cancer, lymphocytic leukemia; lung 
adenocarcinoma, breast and pancreas cancers have been published, there are only a few 
reports with respect to glioblastoma.  Expression profiling of 84 astrocytoma samples 
belonging to different grades and 20 normal adjacent tissue samples and subsequent 
multivariate Cox proportional hazard regression analysis and Kaplan-Meier survival 
analysis identified low expression of miR-181b or miR-106a or high expression of miR-21 to 
be associated with poor patient survival (Zhi et al.). Another recent study analysed the 
miRNA (n=304) expression data from a total of 222 GBM patients derived from The Cancer 
Genome Atlas (TCGA) data set using Cox proportional hazard regression analysis and 
identified a 10 miRNA expression signature that predicted survival (Srinivasan et al.). More 
importantly, using multivariate analysis along with patient age, the 10 miRNA expression 
signature was found to be an independent predictor of patient survival. In addition, the 
authors developed a risk score for each patient based on the expression of each of these ten 
miRNAs and subsequently showed that the risk score could segregate the patients into high 
and low risk groups with significantly different survival times. It was also interesting to 
note that the miRNA set included three miRNAs (miR-20a, miR-106a and miR-17-5p) that 
were protective and seven miRNAs (hsa-miR-31, hsa-miR-222, hsa-miR-148a, hsa-miR-221, 
hsa-miR-146b, hsa-miR-200b and hsa-miR-193a) that were risky with respect to their 
association between their expression and patient survival. The protective miRNAs were 
expressed at an elevated level in the low risk group compared to the high risk group and the 
risky miRNAs were expressed at a higher level in the high risk group than in the low risk 
group. It was suggested that the protective and risky nature of these miRNAs is indicative 
of their functions being either inhibitory or promoting, respectively, of various properties of 
cancer cells like proliferation, migration, invasion etc.   
The use of miRNAs in cancer therapy involves two approaches.  The first approach, which is 
rather more commonly followed, is to inhibit oncogenic miRNAs with a gain of function 
using miRNA antagonists.  The second approach involves reintroduction of a tumour 
suppressor miRNA with the resultant restoration of loss of function.  An interesting view of 
the potential use of miRNA based cancer therapy is that targets that are considered to be 
undruggable could be targeted using miRNA approach.  It was estimated that 
approximately only 20% of all human proteins are targetable by small molecules and 
inhibitory antibodies with the remaining 80% of genes coming under the category that are 
currently considered undruggable (Verdine, 2006). Since the RNA interference based 
approach using miRNAs can essentially target any human gene, this approach opens up a 
large number of potential targets.   
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Several reports have shown the potential use of miRNA-based approach in glioma therapy 
as a proof-of-principle. miR-21 being one of the most upregulated miRNAs in gliomas, with 
anti-apoptotic and pro-invasive functions, appears to be an automatic choice for therapeutic 
interventions. Corsten et al studied the combined effect of inhibiting miR-21 and neural 
precursor cells (NPC)-mediated secretable variant of the cytotoxic agent tumour necrosis 
factor–related apoptosis inducing ligand (S-TRAIL) on glioma (U87) tumour growth using 
an intra-cranial glioma model using athymic mice (Corsten et al., 2007). The ability of U87 
glioma cells to form tumour reduced significantly upon introduction of locked nucleic acid 
(LNA) antimiR-21 oligonucleotides. Further, simultaneous injection of NPCs expressing S-
TRAIL along with miR-21 anti-miR treated U87 cells led to synergistic cytotoxicity with the 
complete elimination of tumour growth. In another study involving a tumour suppressor 
miRNA - miR-34a, its reintroduction into U87 glioma cells led to strong inhibition of tumour 
growth in xenograft models (Li et al., 2009a). miR-296, which belongs to the new family of 
angiomirs, which are proangiogenic, was found to be elevated in human primary brain 
microvascular endothelial cells upon co-culturing with U87 glioma cells (Wurdinger et al., 
2008).  Intravenous administration of miR-296 antagomirs into mice bearing subcutaneous 
U87 tumours resulted in significant reduction of angiogenesis in tumour xenografts 
suggesting the potential utility in glioma therapy. 
6. Conclusions 
miRNAs have generated a huge excitement in the field of cancer biology. During the last six 
years, several studies have established the regulation of miRNAs in glioma development, 
identified their targets and demonstrated their role in cell proliferation, apoptosis, cell cycle 
regulation, migration, invasion and angiogenesis. This indicates that defects in miRNA 
regulatory network appear to play a key role in glioblastoma pathogenesis. Many of these 
studies have clearly showed as a proof-of-concept, the utility of miRNA based approach in 
glioma diagnosis, grading, prognosis and therapy. However, additional studies are needed 
to confirm these findings for the eventual application in clinics. With total number of known 
human miRNAs is 1040 (Release 16, miRBase), one of important needs is to carry out more 
comprehensive analysis of all known miRNAs in large number of tumour tissue samples.  
Efforts towards identifying targets, their experimental validation and establishing the 
relationships with various altered molecular pathways in cancer are also very important. In 
addition to improved understanding of biology of glioma development and progression, 
miRNA study appears to provide newer improved methods useful for variety of purposes 
in clinical medicine. Like with other biomarkers, the use of miRNAs in glioma classification 
and prognosis requires more studies in large cohorts at independent laboratories. The use of 
miRNA based glioma therapy appears to be very highly promising. The development of 
better methods of in vivo delivery of miRNAs is likely to harness the utility of miRNA in 
glioma therapy.  
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